Operator fluency on fresh ground

AngioDynamics, Inc. (ANGO) — this company's answers

The model's full reasoning — Q1 2024 call → NOWe need to determine if the dynamic described is present. The question asks: when analysts probe a recently emerged positive element of the business — something whose meaningful contribution began only within roughly the last few quarters — does management respond with unhesitating, granular operational command, answering follow-up questions with specific, present-tense working detail, while conveying that the element's contribution is still early? Answer YES if all conditions met. We need to identify a recently emerged positive element. The call discusses NanoKnife growth, Auryon growth, mechanical thrombectomy (AngioVac/AlphaVac), etc. Which one is "recently emerged" within last few quarters? Possibly AlphaVac? Or NanoKnife? NanoKnife has been around but maybe its growth is recent? The question says "recently emerged positive element" meaning its meaningful contribution began only within roughly the last few quarters. Let's examine the transcript. Analysts ask about NanoKnife growth: Jayson asks "NanoKnife use is quite strong. I was wondering, if you could break out growth U.S. versus internationally. And internationally, are you seeing it mostly in prostate or are you seeing use in other areas?" Jim responds with some detail about international and U.S., mentions NICE upgrade, etc. Steve gives specific numbers: U.S. disposable growth 28%, international 44%. That is granular. But is NanoKnife "recently emerged"? NanoKnife has been a product for years. The question says "recently emerged positive element" - maybe the PRESERVE study completion? But that's a clinical milestone. The growth of NanoKnife might be recent? Management has been talking about NanoKnife for a while. The question says "whose meaningful contribution began only within roughly the last few quarters" - is that true? The transcript doesn't explicitly say that NanoKnife's meaningful contribution began recently. It says "Our NanoKnife business performed very well and grew approximately 36% during the first quarter" - that's strong growth, but it's not necessarily new. The company has been selling NanoKnife for years. So that might not be "recently emerged." What about AlphaVac? AlphaVac is relatively new. The mechanical thrombectomy business includes AngioVac and AlphaVac. AlphaVac revenue was $1.8 million in the quarter. That's small.

← Back to the full ANGO analysis